Clinical · Molecular biology
Profiling of desmoid tumors reveals frequent mutations in chromatin-remodeling genes and identifies an Immune-myogenic subtype
Summary
This study performed integrated genomic, transcriptomic, and DNA methylation profiling on 76 desmoid tumors (DTs), uncovering frequent mutations in chromatin-remodeling genes, notably KMT2C, in addition to the known CTNNB1 and APC mutations. Transcriptomic analysis identified two robust molecular subtypes: immune-myogenic and mesenchymal-like. The immune-myogenic subtype exhibited high expression of myogenic markers and immune checkpoint genes, alongside enhancer hypomethylation. This subtype is associated with increased immune cell infiltration and predicts a higher responsiveness to immune checkpoint inhibitors.
Critical appraisal
Clinical. This study has significant clinical implications by identifying an immune-myogenic subtype of desmoid tumors that predicts a significantly higher response to immune checkpoint inhibitors (ICIs). Predicted response rates were 58% vs. 26% (p = 0.008) in the primary cohort and 69% vs. 10% (p < 0.001) in an external validation cohort. This suggests that molecular profiling could serve as a predictive biomarker to guide therapeutic strategies, potentially justifying phase II/III clinical trials evaluating ICIs in desmoid tumor patients with this subtype. The time to clinical impact could be 3-5 years, pending prospective validation. BIOMOL : The discovery of frequent mutations in chromatin-remodeling genes, particularly KMT2C (18%), expands our understanding of the molecular basis of desmoid tumors beyond canonical CTNNB1/APC mutations. The study utilized integrated profiling including targeted gene panel sequencing, RNA-seq, and EPIC methylation arrays on desmoid tumor samples, including post-treatment samples. The identification of the immune-myogenic subtype, characterized by high expression of immune checkpoint genes (PDCD1, CD274, CTLA4) and global enhancer hypomethylation, provides molecular targets and underlying mechanisms for immune response. These findings could lead to the development of diagnostic tests based on transcriptomic or methylation profiling to identify patients eligible for immunotherapy.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology